A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

Cited by papers we hold 5

• Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents · 2022
  No notice
• Promoter G-quadruplexes and transcription factors cooperate to shape the cell type-specific transcriptome · 2021
  No notice
• Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents · 2015
  No notice
• Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models · 2012
  No notice
• Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours · 2011
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.